Q-omics provides the consensus-scored ARPP19P1 profile across patient tissues and cancer cell-line models. ARPP19P1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ARPP19P1 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, ARPP19P1 RNA expression shows 5,774 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, and STAD as cancer lineages where ARPP19P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARPP19P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARPP19P1 survival associations across molecular data types. ARPP19P1 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARPP19P1 RNA expression–survival associations across cancer types. High ARPP19P1 expression shows unfavorable associations in BRCA, UCEC, KICH and THYM, but favorable associations in LGG and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ARPP19P1 RNA expression.
This table summarizes ARPP19P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ARPP19P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARPP19P1 shows lower tumor expression in STAD and LIHC. The STAD box plot shows higher ARPP19P1 RNA expression in normal versus tumor tissue (log2 FC = −0.345, t-test p = .005).
This table shows molecular features associated with ARPP19P1 in patient tissues and cancer cell lines. In patient samples, ARPP19P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
